SciBX
Science-Business eXchange

THE DISTILLERY

## This week in techniques

| Approach | Summary | Licensing status | Publication and contact information |
|---|---|---|---|
| **Drug platforms** | | | |
| Nonglycosylated Fc γ-receptor I (CD64; FCGR1)-selective IgG antibodies | Nonglycosylated FCGR1-selective IgG antibodies could be useful for treating cancer and other diseases via mechanisms distinct from standard glycosylated mAbs. *In vitro*, a nonglycosylated variant of Herceptin trastuzumab increased dendritic cell (DC)-mediated killing of a human breast carcinoma cell line compared with no antibody. In contrast, Herceptin and a glycosylated trastuzumab variant did not induce DC-mediated killing of the cancer cells. Next steps could include assessing the ability of nonglycosylated antibodies to induce adaptive immune responses and evaluating their efficacy in a mouse model of human tumors.<br>Herceptin, a humanized mAb against HER2 (ERBB2; neu) from Roche's Genentech Inc. unit, is marketed to treat breast cancer and is under EMEA review for stomach cancer. | Two patent applications filed; available for licensing from Clayton Biotechnologies Inc. | Jung, S.T. *et al. Proc. Natl. Acad. Sci. USA*; published online Dec. 14, 2009; doi:10.1073/pnas.0908590107<br>**Contact:** George Georgiou, University of Texas, Austin, Texas<br>e-mail: gg@che.utexas.edu |

*SciBX* 3(1); doi:10.1038/scibx.2010.32
Published online Jan. 7, 2010